Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2-expression”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableLooking for participantsNCT06762977
What this trial is testing

A Composite Assay for HER2-positive Early-stage Breast Cancer Management

Who this might be right for
Breast Cancer Early Stage Breast Cancer (Stage 1-3)HER2
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 180
Testing effectiveness (Phase 2)Study completedNCT02491892
What this trial is testing

Pertuzumab in Participants With Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 79
Testing effectiveness (Phase 2)Enrolling By InvitationNCT07292571
What this trial is testing

Evaluation of Different Types of HER2 Expression in Breast Cancer Using [99mTc]Tc -ZHER2:4107

Who this might be right for
Primary Breast Cancer
Tomsk National Research Medical Center of the Russian Academy of Sciences 50
Not applicableNot Yet RecruitingNCT07689929
What this trial is testing

Research on AI Models for Predicting Breast Cancer Treatment Effectiveness to Guide Her-2 Targeted ADC Therapy

Who this might be right for
Breast Cancer
Zhejiang Cancer Hospital 900
Testing effectiveness (Phase 2)UnknownNCT06063018
What this trial is testing

RC48 Combined With Tislelizumab for Second-line Treatment of HER2 Expression in Recurrent Cervical Cancer

Who this might be right for
Cervical Cancer Recurrent
Peking Union Medical College Hospital 30
Testing effectiveness (Phase 2)Study completedNCT00795899
What this trial is testing

Taxol Epirubicin Cyclophosphamide Herceptin Neoadjuvant (TECHNO)

Who this might be right for
Breast Cancer
GBG Forschungs GmbH 230
Testing effectiveness (Phase 2)UnknownNCT05957757
What this trial is testing

RC48 Combined With Tislelizumab for Bladder Sparing Treatment in NMIBC With BCG Treatment Failure and HER2 Expression

Who this might be right for
Non-Muscle Invasive Bladder CancerHER2
RenJi Hospital 20
Testing effectiveness (Phase 2)Looking for participantsNCT05403242
What this trial is testing

RC48-ADC Combined With S-1 for First-line Treatment of Advanced Gastroesophageal Adenocarcinoma With Moderate Expression of HER2

Who this might be right for
Advanced Gastroesophageal Adenocarcinoma
Chinese PLA General Hospital 42
Not applicableStudy completedNCT01064349
What this trial is testing

Breast Cancer With Over-expression of erbB2-BRAINSTORM

Who this might be right for
Cancer
GlaxoSmithKline 144
Not applicableUnknownNCT01424865
What this trial is testing

Cancer Stem Cell Biomarkers as a Predictor of Response to Trastuzumab in Samples From Patients With Breast Cancer Previously Treated in the NSABP-B-31 Trial

Who this might be right for
Breast Cancer
NSABP Foundation Inc 1,874
Early research (Phase 1)Looking for participantsNCT06500052
What this trial is testing

BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointestinal Cancer and Other Solid Tumors

Who this might be right for
Esophageal CancerGastric CancerPancreatic Cancer+2 more
Sichuan Baili Pharmaceutical Co., Ltd. 20
Testing effectiveness (Phase 2)Looking for participantsNCT07817082
What this trial is testing

Phase II Study of SHR-A1811 for Ultra-Low HER2 Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer With Ultra-Low HER2 Expression
Tianjin Medical University Cancer Institute and Hospital 30
Early research (Phase 1)Looking for participantsNCT05940896
What this trial is testing

RC48-ADC Combined With Radiotherapy in the Treatment of Locally Advanced Solid Tumors With HER2 Expression

Who this might be right for
Solid Tumor
RemeGen Co., Ltd. 24
Not applicableUnknownNCT05834699
What this trial is testing

HER2 Expression of CTC to Predict Response in HER2-low Advanced Breast Cancer Patients Treated With ADC

Who this might be right for
Breast Cancer
Beijing 302 Hospital 50
Testing effectiveness (Phase 2)Looking for participantsNCT05671822
What this trial is testing

Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2 Expression Gastric Cancer

Who this might be right for
HER2 Expression Gastric Cancer/Gastroesophageal Junction Adenocarcinoma
Suzhou Suncadia Biopharmaceuticals Co., Ltd. 258
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07189884
What this trial is testing

Pyrotinib Maleate Tablets in Combination With Dalpiciclib Isethionate Tablets and Standard Endocrine Therapy

Who this might be right for
Locally Advanced Breast Cancer (LABC)
The First Affiliated Hospital of Xiamen University 33
Testing effectiveness (Phase 2)UnknownNCT05979740
What this trial is testing

RC48 Combined With Toripalimab and Radiotherapy for Bladder Sparing Treatment in MIBC

Who this might be right for
Muscle Invasive Bladder CancerHER2 ExpressionRadiotherapy+2 more
RenJi Hospital 6
Testing effectiveness (Phase 2)Active Not RecruitingNCT04872985
What this trial is testing

Pyrotinib Plus Neoadjuvant Chemotherapy in HR+/HER2-, HER4-High Breast Cancer

Who this might be right for
Breast CancerHormone-receptor Positive Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 140
Testing effectiveness (Phase 2)Looking for participantsNCT07653685
What this trial is testing

A Clinical Trial Evaluating TQB2930 Injection and Chemotherapy With or Without Bevacizumab in Patients With HER2-Abnormally Expressed Unresectable Locally Advanced or Metastatic Colorectal Cancer.

Who this might be right for
Colorectal Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. 71
Testing effectiveness (Phase 2)UnknownNCT05845138
What this trial is testing

SHR-A1811 Combined With Capecitabine in Treatment of Unresectable or Metastatic Breast Cancer With Low HER2 Expression.

Who this might be right for
Breast Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd. 116
Next Page